Stockscreener 앱 받기
12.57
0.40%
0.05
시간 외 거래:
12.42
-0.15
-1.19%
전일 마감가:
$12.52
열려 있는:
$12.57
하루 거래량:
1.50M
Relative Volume:
0.59
시가총액:
$4.01B
수익:
$3.05B
순이익/손실:
$181.32M
주가수익비율:
33.64
EPS:
0.3737
순현금흐름:
$225.64M
1주 성능:
-5.20%
1개월 성능:
+6.08%
6개월 성능:
+22.63%
1년 성능:
+68.05%
1일 변동 폭
$12.52
$13.03
1주일 범위
$12.35
$13.85
52주 변동 폭
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.57 | 3.99B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.36 | 52.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.87 | 49.15B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.49 | 42.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.26 | 35.68B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
566.99 | 24.86B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | UBS | Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
BlackRock (NYSE: AMRX) holds 24.1M shares, 7.6% stake reported - Stock Titan
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
AMRX Should I Buy - Intellectia AI
Amneal initiates nationwide settlement for opioid-related claims - MSN
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown - Yahoo Finance
Amneal Kashiv Deal Shifts Biosimilar Growth And Valuation Story - Sahm
UBS initiates coverage of Amneal Pharmaceuticals (AMRX) with buy recommendation - MSN
Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal - MSN
Amneal Acquires Kashiv BioSciences for $750 Million Upfront - HarianBasis.co
Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push - MarketBeat
AMRX Price Today: Amneal Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Amneal Pharma to acquire Kashiv BioSciences to create fully integrated global biosimilar leader - MSN
2DT Stock Price and Chart — TRADEGATE:2DT - TradingView
Why Is Amneal Pharmaceuticals Stock Gaining Today? - Sahm
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results - Yahoo Finance
Amneal agrees to buy Kashiv BioSciences - The Pharma Letter
Amneal to acquire Kashiv BioSciences in biosimilar expansion By Investing.com - Investing.com India
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal - 1470 & 100.3 WMBD
Amneal Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AMRX) 2026-04-22 - Seeking Alpha
AMRX.N Technical Analysis & Stock Price Forecast - Intellectia AI
AMRX.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AMRX News & Events - Intellectia AI
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Business Standard
4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy - Law360
AMRX: Acquisition establishes a US biosimilars leader, targeting $1–1.3B in biosimilar revenue by 2030 - TradingView
Kashiv BioSciences to be acquired by Amneal Pharmaceuticals - ROI-NJ
Amneal Pharmaceuticals (NASDAQ:AMRX) Issues Earnings Results - MarketBeat
Amneal Pharmaceuticals to Acquire Kashiv BioSciences, Creating a Global Biosimilar Leader and Raising 2026 Financial Guidance - Minichart
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates Q1 2026 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.90%
2.19%
자본화:
|
볼륨(24시간):